# Maribavir treatment for refractory and drug-intolerant cytomegalovirus viremia and disease after allogeneic hematopoietic stem cell transplantation: a clinical analysis of 25 cases

## TL;DR

This study shows maribavir is safe and effective for treating CMV infections in patients who don't respond to or can't tolerate standard drugs after stem cell transplants.

## Contribution

The study provides clinical evidence for maribavir's use in refractory and drug-intolerant CMV cases post-transplant.

## Key findings

- Maribavir was effective in all 25 patients with refractory or drug-intolerant CMV.
- Most patients experienced CMV viremia around 120 days post-transplant with high viral loads.
- Only minor side effects like taste changes and mild bone marrow suppression were observed.

## Abstract

探讨马立巴韦治疗异基因造血干细胞移植（allo-HSCT）后难治性、对常规抗病毒药物不耐受的巨细胞病毒（cytomegalovirus，CMV）血症和CMV病的安全性和有效性。

回顾性分析2024年4月至2024年9月在河北燕达陆道培医院马立巴韦治疗allo-HSCT后的难治性、对常规抗病毒药物不耐受的CMV血症和CMV病的结局。

接受马立巴韦治疗的25例患者，其中亲缘单倍型移植21例，同胞全合移植2例，非血缘移植2例。1次移植21例，2次移植2例和3次移植2例。患者发生CMV血症的中位时间为移植后120.5（6～298）d，血浆CMV最高拷贝中位数为6 400（1 100～650 000）拷贝/ml。6例患者诊断CMV病。患者在CMV感染后的9.5（1～41）d开始使用马立巴韦。使用马立巴韦持续中位时间为11.5（6～43）d。25例患者治疗均有效。2例患者发生1级的味觉异常，1例发生2级骨髓抑制。

allo-HSCT后难治性、药物不耐受的CMV血症和CMV病患者应用马立巴韦治疗安全有效。